Patricia Keegan

15.4k total citations · 4 hit papers
140 papers, 9.3k citations indexed

About

Patricia Keegan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Patricia Keegan has authored 140 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 31 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Patricia Keegan's work include Lung Cancer Treatments and Mutations (32 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Cardiac Valve Diseases and Treatments (27 papers). Patricia Keegan is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Cardiac Valve Diseases and Treatments (27 papers). Patricia Keegan collaborates with scholars based in United States, Canada and China. Patricia Keegan's co-authors include Richard Pazdur, Steven J. Lemery, Martin H. Cohen, Gideon M. Blumenthal, Kun He, Leigh Marcus, Dickran Kazandjian, Hong Zhao, Yuan Li Shen and Rajeshwari Sridhara and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Patricia Keegan

135 papers receiving 9.1k citations

Hit Papers

FDA Approval Summary: Pembrolizumab for the Treatment of ... 2016 2026 2019 2022 2019 2017 2016 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
    2019 789 citations Steven J. Lemery, Patricia Keegan et al. Clinical Cancer Research profile →
  2. First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
    2017 457 citations Steven J. Lemery, Patricia Keegan et al. profile →
  3. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
    2016 337 citations Gideon M. Blumenthal, Sirisha L. Mushti et al. The Oncologist profile →
  4. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
    2016 285 citations Joohee Sul, Gideon M. Blumenthal et al. The Oncologist profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patricia Keegan United States 54 5.0k 3.1k 2.1k 1.6k 1.3k 140 9.3k
Rajeshwari Sridhara United States 53 4.8k 1.0× 2.9k 0.9× 3.0k 1.5× 1.3k 0.8× 788 0.6× 137 9.3k
Christophe Le Tourneau France 46 4.9k 1.0× 2.3k 0.7× 2.1k 1.0× 1.6k 1.0× 1.3k 1.0× 335 8.7k
Bhumsuk Keam South Korea 50 6.1k 1.2× 4.0k 1.3× 2.1k 1.0× 1.6k 1.0× 1.2k 1.0× 373 9.9k
Anthony Elias United States 50 5.9k 1.2× 3.5k 1.1× 2.2k 1.1× 2.0k 1.2× 735 0.6× 205 9.8k
Zhengjia Chen United States 51 3.1k 0.6× 2.5k 0.8× 2.4k 1.2× 989 0.6× 816 0.6× 267 8.3k
Siqing Fu United States 51 4.1k 0.8× 2.4k 0.8× 3.8k 1.9× 2.4k 1.5× 954 0.7× 412 9.6k
Daniel D. Karp United States 43 4.8k 1.0× 3.8k 1.2× 2.9k 1.4× 1.6k 1.0× 565 0.4× 217 9.4k
Gideon M. Blumenthal United States 47 4.0k 0.8× 2.6k 0.8× 2.4k 1.2× 1.3k 0.8× 926 0.7× 119 7.5k
Justin F. Gainor United States 55 6.6k 1.3× 6.6k 2.1× 3.4k 1.6× 2.1k 1.3× 1.1k 0.8× 235 10.6k
Tae‐You Kim South Korea 48 4.3k 0.9× 2.5k 0.8× 2.0k 1.0× 1.5k 0.9× 575 0.4× 189 7.6k

Countries citing papers authored by Patricia Keegan

Since Specialization
Citations

This map shows the geographic impact of Patricia Keegan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Keegan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Keegan more than expected).

Fields of papers citing papers by Patricia Keegan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Keegan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Keegan. The network helps show where Patricia Keegan may publish in the future.

Co-authorship network of co-authors of Patricia Keegan

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Keegan. A scholar is included among the top collaborators of Patricia Keegan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Keegan. Patricia Keegan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Naing, Aung, Amit Mahipal, Milind Javle, et al.. (2025). Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study. PubMed. 8(1). 71–81.
2.
Li, Lili, Ming Song, Qun Zhao, et al.. (2023). Flat dose regimen of toripalimab based on model-informed drug development approach. Frontiers in Pharmacology. 13. 1069818–1069818. 3 indexed citations
3.
Ravindranathan, Sruthi, Xiaoguang Wang, Daniel J. Chin, et al.. (2023). 468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status. SHILAP Revista de lepidopterología. A522–A526. 1 indexed citations
4.
Batchelor, Wayne, Carlos E. Sanchez, Paul Sorajja, et al.. (2021). TCT-451 Thirty-Day Outcomes After Next-Day Discharge in Transcatheter Aortic Valve Replacement: Analysis of the STS/ACC TVT Registry. Journal of the American College of Cardiology. 78(19). B185–B186.
5.
Nair, Abhilasha, Kelie Reece, Martha Donoghue, et al.. (2020). FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma. The Oncologist. 26(3). e484–e491. 61 indexed citations
6.
Bradford, Diana, Suzanne Demko, Susan Jin, et al.. (2020). FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma. The Oncologist. 25(7). e1077–e1082. 24 indexed citations
7.
Kluetz, Paul G., Patricia Keegan, George D. Demetri, et al.. (2020). FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs. Clinical Cancer Research. 27(4). 916–921. 8 indexed citations
8.
Lauck, Sandra, Janarthanan Sathananthan, Julie Park, et al.. (2019). Post‐procedure protocol to facilitate next‐day discharge: Results of the multidisciplinary, multimodality but minimalist TAVR study. Catheterization and Cardiovascular Interventions. 96(2). 450–458. 23 indexed citations
9.
Beaver, Julia A., Maitreyee Hazarika, Flora Mulkey, et al.. (2018). Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. The Lancet Oncology. 19(2). 229–239. 112 indexed citations
10.
Corrigan, Frank, John Lisko, Salim S. Hayek, et al.. (2018). Mean Aortic pressure gradient and global longitudinal strain recovery after transcatheter aortic valve replacement – A retrospective analysis. Hellenic Journal of Cardiology. 59(5). 268–271. 6 indexed citations
11.
Odogwu, Lauretta, Luckson Mathieu, Gideon M. Blumenthal, et al.. (2018). FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. The Oncologist. 23(6). 740–745. 166 indexed citations
12.
Pelosof, Lorraine, Steven J. Lemery, Sandra J. Casak, et al.. (2018). Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib. The Oncologist. 23(4). 496–500. 15 indexed citations
13.
Odogwu, Lauretta, Luckson Mathieu, Kirsten B. Goldberg, et al.. (2017). FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. The Oncologist. 23(3). 353–359. 49 indexed citations
14.
Pai-Scherf, Lee H., Gideon M. Blumenthal, Hongshan Li, et al.. (2017). FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. The Oncologist. 22(11). 1392–1399. 228 indexed citations
15.
16.
Sul, Joohee, Paul G. Kluetz, Elektra J. Papadopoulos, & Patricia Keegan. (2015). Clinical outcome assessments in neuro-oncology: a regulatory perspective. Neuro-Oncology Practice. 3(1). 4–9. 10 indexed citations
17.
Babaliaros, Vasilis, Chandan Devireddy, Stamatios Lerakis, et al.. (2014). Comparison of Transfemoral Transcatheter Aortic Valve Replacement Performed in the Catheterization Laboratory (Minimalist Approach) Versus Hybrid Operating Room (Standard Approach). JACC: Cardiovascular Interventions. 7(8). 898–904. 230 indexed citations
18.
Axelson, Michael D., Ke Liu, Xiaoping Jiang, et al.. (2013). U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma. Clinical Cancer Research. 19(9). 2289–2293. 140 indexed citations
19.
20.
Gould, R. Gordon, G. Leroy, George T. Okita, et al.. (1955). The use of C14-labeled acetate to study cholesterol metabolism in man.. PubMed. 46(3). 372–84. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajeshwari Sridhara Breakdown of academic impact, for papers by Christophe Le Tourneau Breakdown of academic impact, for papers by Bhumsuk Keam Breakdown of academic impact, for papers by Anthony Elias Breakdown of academic impact, for papers by Zhengjia Chen Breakdown of academic impact, for papers by Siqing Fu Breakdown of academic impact, for papers by Daniel D. Karp Breakdown of academic impact, for papers by Gideon M. Blumenthal Breakdown of academic impact, for papers by Justin F. Gainor Breakdown of academic impact, for papers by Tae‐You Kim
Rankless by CCL
2026